financetom
Business
financetom
/
Business
/
Lyft inks deals with Mobileye, others to bring robotaxis to ridehail platform
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Lyft inks deals with Mobileye, others to bring robotaxis to ridehail platform
Nov 9, 2024 11:18 AM

(Reuters) - Lyft ( LYFT ) said on Wednesday it will partner with Mobileye and two other companies in the robotaxi industry to bring self-driving cars onto its ridehail platform and bolster research and development in the sector.

The app-based taxi platform will incorporate cars owned by third-party fleet operators, equipped with the Mobileye Drive self-driving system, as it looks to compete with rival Uber ( UBER ), which has signed a slew of autonomous taxi agreements.

Lyft ( LYFT ), which is set to report quarterly results after markets close, said it will also collaborate with May Mobility to deploy self-driving taxis in Atlanta starting next year.

It will also work with Nexar, which designs products that improve driving by using machine learning and computer vision, to explore how the companies can bolster research and development in the autonomous vehicle industry using Lyft's ( LYFT ) fleet data and the technology firm's bank of vehicle video footage.

Lyft's ( LYFT ) series of agreements follows market leader Uber's ( UBER ) expansion of partnership with Alphabet's Waymo and new deals General Motors' Cruise and China's WeRide among others to cement its lead in the robotaxi segment.

Analysts and industry experts have cautioned that developing autonomous driving systems and robotaxis will be challenging and time-consuming due to engineering and regulatory hurdles.

Electric vehicle maker Tesla last month unveiled its Cybercab robotaxi concept, slated for production in 2026, and has begun testing ridehail services with employees in San Francisco.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Once a beacon of stability, Vietnam to name third president in a year
Once a beacon of stability, Vietnam to name third president in a year
Mar 22, 2024
HANOI, March 22 (Reuters) - Communist-ruled Vietnam is seeking its third president in little more than a year after the resignation of Vo Van Thuong, who was only elected last year after the sudden dismissal of his predecessor. With accumulated foreign direct investment higher than its gross domestic product, Vietnam's stability is crucial to multinationals with large operations in the...
Japan's union group Rengo announces biggest wage hikes on record
Japan's union group Rengo announces biggest wage hikes on record
Mar 22, 2024
TOKYO (Reuters) -Japanese firms have agreed to raise pay by 5.25% this year, the biggest rise under comparable data since 2013, the country's largest union group Rengo confirmed on Friday. The results of the closely-watched wage negotiations are announced in several stages, in which the blue-chip firms are first to wrap up their talks in mid-March. The second announcement on...
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Mar 22, 2024
(Reuters) - Popular investor Cathie Wood's ARK Invest bought nearly 10,000 shares of Reddit ( RDDT ) in the social media platform's strong market debut on Thursday, an email from the asset manager showed. A total of 9,982 shares of the loss-making company was added to ARK Next Generation Internet ETF ( ARKW ) and ARK Fintech Innovation ETF (...
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Mar 22, 2024
05:04 AM EDT, 03/22/2024 (MT Newswires) -- Hutchmed ( HCM ) said late Thursday it has started the registration stage for a phase 2/3 clinical trial of investigational drug sovleplenib for adult patients with warm antibody autoimmune hemolytic anemia in China. The move follows positive data from the proof-of-concept phase 2 stage of the trial and a consultation with the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved